DonaldNegroskiMD

PubMed

• Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
  Barry A Singer, Douglas L Arnold, Jelena Drulovic, Mark S Freedman, Ralf Gold, Mark Gudesblatt, Elzbieta Jasinska, Christopher C LaGanke, Robert T Naismith, Donald Neg...> ;Multiple Sclerosis. 2023 Dec 1
• Correction to: Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
  Penny Pennington, Bianca Weinstock-Guttman, Channa Kolb, Dejan Jakimovski, Katherine Sacca, Ralph H B Benedict, Svetlana Eckert, Marc Stecker, Alexis Lizarraga, Michae...> ;Journal of Neurology. 2023 Feb 1
• 2 citations
  Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
  Regina Berkovich, Donald Negroski, Daniel Wynn, Daniel Sellers, Kristen G Bzdek, Alex L Lublin, Andreea M Rawlings, Cuc Quach, Danelle P Wells, Melanie Dumlao, Adriana...> ;Multiple Sclerosis and Related Disorders. 2023 Feb 1
• 1 citations
  Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
  Penny Pennington, Bianca Weinstock-Guttman, Channa Kolb, Dejan Jakimovski, Katherine Sacca, Ralph H B Benedict, Svetlana Eckert, Marc Stecker, Alexis Lizarraga, Michae...> ;Journal of Neurology. 2023 Feb 1
• Thalamic atrophy measured by artificial intelligence in a multicentre clinical routine real-word study is associated with disability progression.
  Zivadinov R, Bergsland N, Jakimovski D, Weinstock-Guttman B, Benedict RHB, Riolo J, Silva D, Dwyer MG, DeepGRAI Registry Study group> ;Journal of neurology, neurosurgery, and psychiatry. 2022-07-28
• 14 citations
  Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
  Sibyl Wray, Florian Then Bergh, Annette Wundes, Douglas L Arnold, Jelena Drulovic, Elzbieta Jasinska, James D Bowen, Donald Negroski, Robert T Naismith, Samuel F Hunte...> ;Advances in Therapy. 2022 Apr 1
• Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
  Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperso...> ;Neurology.
• Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
  Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM Study Investigators> ;The New England journal of medicine.
• Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
  Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA, CARE-MS II Investigators> ;Neurology. 2016-10-12
• Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
  Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Viglietta V, Daw...> ;Neurology. 2015-02-13
• Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
  Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, TOWER Trial Group> ;The Lancet. Neurology. 2014-01-23
• Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
  Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oy...> ;Lancet (London, England). 2012-11-01
• Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
  Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF,...> ;Multiple sclerosis (Houndmills, Basingstoke, England). 2008-01-21
• 57 citations
  Amyotrophic lateral sclerosis Effects of acute intravenous and chronic subcutaneous administration of thyrotropin‐releasing hormone in controlled trials
  Hiroshi Mitsumoto, Efrain Salgado, Donald Negroski, Maurice R. Hanson, Virgilio D. Salanga, John F. Wilber, Asa J. Wilbourn, Anthony C. Breuer, Judy Leatherman> ;Neurology. 1986 Feb 1
• Join now to see all